Be in the know. 10 key reads for Thursday…

  1. Why Star Of Magic Lance Burton Thinks Practice Doesn’t Make Perfect (Investor’s Business Daily)
  2. The Stock Market Had an Awful September. Here’s What History Says Happens Next. (Barron’s)
  3. Regeneron’s Good News on Covid Antibodies Is Positive for Vaccines, Too (Barron’s)
  4. Ford cuts price of 2021 Mustang Mach-E: Here’s the breakdown (USA Today)
  5. The US economy doesn’t need more fiscal stimulus for a V-shaped recovery, veteran strategist Ed Yardeni says (Business Insider)
  6.  New Proteomics Analysis May Show How Ivermectin Fights COVID-19 (TrialSiteNews)
  7. Trump Could Get His Vaccine Before Election Day (Bloomberg)
  8. China’s Economic Rebound Picks Up Pace (Wall Street Journal)
  9. Cézanne, Picasso and a T. Rex—This Auction Season, Anything Goes (Wall Street Journal)
  10. Value Stocks Are Outperforming Growth—at Least for Now (Wall Street Journal)

Be in the know. 12 key reads for Wednesday…

  1. Regeneron says antibody ‘cocktail’ helps COVID-19 patients recover quickly (New York Post)
  2. COVID-19 vaccine timelines hinge on how trials, FDA approvals work (New York Post)
  3. Why a V-Shaped Economic Recovery Is Still on Track (Barron’s)
  4. Why billionaire investor Leon Cooperman says there are ‘three stock markets,’ as he warns about danger in FAANG stocks (MarketWatch)
  5. Companies added better than expected 749,000 jobs amid jump in construction, hospitality, ADP says (CNBC)
  6. China’ factory activity grows sharply in September (MarketWatch)
  7. China’s services PMI rises for 7th straight month (MarketWatch)
  8. Pelosi, Mnuchin Resume Talks on Relief Package (Barron’s)
  9. Analyst who called rally off March bottom now sees this as the level to watch for stocks (Yahoo! Finance)
  10. Mymensingh Medical College Retrospective Study: Ivermectin Superior to Standard of Care for COVID-19 Patients (TrialSiteNews)
  11. Value Stocks Have Room for More Gains – BofA Securities (Street Insider)
  12. The Chevy Chevelle That Proved Its Worth (Wall Street Journal)